Alivus Life Sciences (ALVUS) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 began with a 9.7% sequential revenue growth, signaling recovery after a challenging Q4 FY24, with broad-based growth across geographies and segments, especially in Generic API and CDMO.

• Profit for Q1 FY25 was ₹1,114.83 million, up from Q4 FY24 but down from Q1 FY24.

• The company is focused on capacity expansion, pipeline development, and has added five new products, including high-potency APIs.

• GPL, Non-GPL, and CDMO segments all performed well, supporting expectations for steady growth and stable margins in FY25.

• The company operates a single segment: Active Pharmaceutical Ingredient (API).

Financial highlights

• Revenue from operations for Q1 FY25 was ₹5,886.16 million, up 9.7% quarter-over-quarter and 1.8% year-over-year.

• EBITDA stood at ₹1,650 million, up 14.1% sequentially, with a margin of 28%.

• PAT was ₹1,114.83 million, with a PAT margin of 18.9%.

• Gross profit margin was 51.1%, down from 55.5% in Q4 FY24 and 57.1% YoY.

• Free cash flow was ₹1,213 million; cash and equivalents at ₹4,263 million as of June 30, 2024.

Outlook and guidance

• Growth momentum is expected to continue, with stable margins anticipated for FY25.

• CDMO business is expected to see commercial supplies from new projects in Q3/Q4, with revenue potential of $12 million from two projects.

• CapEx for FY25 is projected at ₹3,000-3,500 million, with similar levels for FY26.

• The company has achieved the minimum public shareholding requirement post-IPO.